Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them

Journal of the National Cancer Institute

Volumn 108, Issue 3, 2016, Pages

  Etzioni, Ruth ^a   Gulati, Roman ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER OVERDIAGNOSIS; CANCER SCREENING; FOLLOW UP; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; BREAST NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; NEOPLASMS; PROCEDURES; RADIOGRAPHY; STANDARDS; STATISTICAL MODEL; TIME FACTOR; TRENDS;

BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; LIKELIHOOD FUNCTIONS; MAMMOGRAPHY; MASS SCREENING; MEDICAL OVERUSE; NEOPLASMS; TIME FACTORS;

EID: 84962503131     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv345     Document Type: Review

References (43)

1. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38(4):625-651.
2. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
3. Gotzsche PC, Jorgensen KJ, Zahl PH. Lead-time models produce far too low estimates of overdiagnosis with mammographic screening. J Am Coll Radiol. 2014;11(11):1098.
4. Kopans DB. Point: The New England Journal of Medicine article suggesting overdiagnosis from mammography screening is scientifically incorrect and should be withdrawn. J Am Coll Radiol. 2013;10(5):317-319; discussion 323.
5. Kopans DB. Arguments Against Mammography Screening Continue to be Based on Faulty Science. Oncologist. 2014;19(2):107-112.
6. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer. 2013;109(7):2014-2019.
7. Zahl PH, Jorgensen KJ, Gotzsche CO. Lead-time models should not be used to estimate overdiagnosis in cancer screening. J Gen Intern Med. 2014.
8. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33(1):111-121.
9. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587.
10. Etzioni R, Gulati R, Mallinger L, et al. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158(11):831-838.
11. Morrell S, Barratt A, Irwig L, et al. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control. 2010;21(2):275-282.
12. Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. New Engl J Med. 2012;367(21):1998-2005.
13. Kalager M, Adami H-O, Bretthauer M, et al. Overdiagnosis of Invasive Breast Cancer due to Mammography Screening. Ann Intern Med. 2012;157(3):221-222.
14. Njor SH, Olsen AH, Blichert-Toft M, et al. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ. 2013;346:f1064.
15. Zackrisson S, Andersson I, Janzon L, et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: followup study. BMJ. 2006;332(7543):689-692.
16. Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
17. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res. 2013;15(3):R41.
18. Smith RA. Counterpoint: Overdiagnosis in breast cancer screening. J Am Coll Radiol. 2014;11(7):648-652.
19. Etzioni R, Gulati R. Oversimplifying Overdiagnosis. J Gen Intern Med. 2014;29(9):1218-1220.
20. Biesheuvel C, Barratt A, Howard K, et al. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 2007;8(12):1129-1138.
21. Puliti D, Miccinesi G, Paci E. Overdiagnosis in breast cancer: design and methods of estimation in observational studies. Prev Med. 2011;53(3):131-133.
22. Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika. 1969;56(3):601-614.
23. Shen Y, Zelen M. Screening Sensitivity and Sojourn Time From Breast Cancer Early Detection Clinical Trials: Mammograms and Physical Examinations. J Clin Oncol. 2001;19(15):3490-3499.
24. Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics. 2004;5(4):603-613.
25. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics. 2005;61(4):992-999.
26. Duffy SW, Agbaje O, Tabar L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7(6):258-265.
27. Seigneurin A, Francois O, Labarere J, et al. Overdiagnosis from nonprogressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011;343:d7017.
28. Pinsky PF. Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics. 2001;57(2):389-395.
29. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
30. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
31. Etzioni R, Xia J, Hubbard R, et al. A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst. 2014;106(12):dju315 doi:10.1093/jnci/dju315.
32. Baker S.G.,Prorok P.C.,Kramer B.S. Lead time and overdiagnosis J Natl Cancer Inst. 2014 106 12 dju346,10.1093/jnci/dju346.
33. Baker SG, Prorok PC, Kramer BS. Lead time and overdiagnosis. J Natl Cancer Inst. 2014;106(12):dju346 doi:10.1093/jnci/dju346.
34. Duffy SW. Screening, Sojourn Time. In. Encyclopedia of Biostatistics: John Wiley & Sons, Ltd; 2005.
35. Munoz DF, Near AM, van Ravesteyn N, et al. Effects of screening and adjuvant therapy on US breast cancer specific mortality by estrogen receptor status. JNCI. 2014;106(11):dju289 doi:10.1093/jnci/dju289.
36. van Ravesteyn NT, Schechter CB, Near AM, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev. 2011;20(1):112-122.
37. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014;161(2):104-112.
38. Mandelblatt J, Cronin K, de Koning H, et al. Modeling Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. In: Services USDoHaH, (ed); 2015, 1-58.
39. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
40. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
41. de Snoo F, Bender R, Glas A, et al. Gene expression profiling: decoding breast cancer. Surg Oncol. 2009;18(4):366-378.
42. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(Suppl 3):S141-S145.
43. Paci E, Miccinesi G, Puliti D, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res. 2006;8(6):R68.